A study has suggested that while funding for artificial intelligence in pharma was $5.2bn in 2019, overall investment is slowing.
List view / Grid view
Filter the results
The ECMC has published guidelines for Complex Innovative Design trails which could improve the conduct, quality and acceptability of oncology studies, enabling patients to get access to new medications more quickly.
A new report from the FDA has shown that greater competition among generic drug makers is associated with lower generic drug prices.
A new study could aid pharmaceutical companies in their drug development efforts after if found that a drug candidate is more likely to be approved for use if it targets a gene known to be linked to the disease.
According to a new report, the UK is leading the rest of Europe for early-stage clinical research into new medicines and vaccines, with more than 600 commercial clinical trials taking place in the NHS.
A methodology has been developed which characterises how drugs influence each other when combined during treatment and sheds new light on how drugs perturb the underlying molecular networks.
New data shows the non-inferiority of efficacy for the subcutaneous (SC) formulation of CT-P13 to the intravenous (IV) formulation of CT-P13 in people with rheumatoid arthritis.
Lonza to host new webinar – “Paper to EBR in nine months: how a strong collaboration leads to project success”
Free Lonza webinar to discuss the benefits of a collaborative approach to implementing an Electronic Batch Record Platform.
Aducanumab, an Alzheimer's disease treatment, will be submitted as part of a Biologics License Application after meeting clinical trial primary endpoints.
We’re getting closer to something special with regard to how we manufacture biopharmaceuticals. Loe Cameron explores where the continuous bioprocessing journey could take us and what it might mean for medicine manufacturers worldwide.
A late-stage clinical trial for Imfinzi and an experimental treatment has not extended the lives of patients with advanced non-small cell lung cancer.
PharmaIntegrity™ is the definitive solution for managing the collection, analysis, and trending of environmental monitoring data, ensuring timely detection of problems in production, facilitating product release and reducing risks and costs associated with product loss and recalls.
New article says that to take full advantage of deep-learning solutions in healthcare, the US and China should collaborate, not compete.